Search En/Fr

Healthcare Change Category

Power your medicine

Products Portfolio

Clinical Research

With its product NBTXR3, Nanobiotix is currently running trials in several indications across Europe, the USA and the Asia-Pacific Region: a registration trial in Soft Tissue Sarcoma, and Phase I/II trials in Liver cancers (HCC and Metastatic), Head and Neck cancers, Prostate cancer and in Asia via its partner PharmaEngine, Rectal cancer and Head and Neck cancers treated by radiotherapy plus chemotherapy.

NBTXR3 – Soft Tissue Sarcoma – Phase I/II

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity

clinicaltrials.gov | Phase I/II | France | Completed

NBTXR3 – Soft Tissue Sarcoma – Phase  II/III

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

actinsarc.com | clinicaltrials.gov | Reg. phase | EU, South Africa, Asia-Pacific | Recruiting

NBTXR3 – Head and Neck cancer – Phase I/II

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

clinicaltrials.gov | Phase I/II | France, Spain | Recruiting

NBTXR3 – HepatoCellular Cancer – Phase I/II

A Phase I-II study of NBTXR3 activated by Stereotactic Body Radiation Therapy (SBRT) in the treatment of Liver Cancers

clinicaltrials.gov | Phase I/II | France | Recruiting

NBTXR3 – Liver Metastases – Phase I/II

A Phase I-II study of NBTXR3 activated by Stereotactic Body Radiation Therapy (SBRT) in the treatment of Liver cancers

clinicaltrials.gov | Phase I/II | France | Recruiting

NBTXR3 – Prostate cancer – Phase I/II

A Phase I-II Dose Escalation Study of NBTXR3 Activated by External Beam Radiation Therapy or External Beam Radiotherapy with Brachytherapy in Subjects with Newly Diagnosed Unfavorable Intermediate Risk or High Risk Prostate Adenocarcinoma Treated with Androgen Deprivation

clinicaltrials.gov | Phase I/II | USA | Recruiting

00

PROSTATE CANCER

NBTXR3 – Rectal cancer – Phase I/II – Sponsored by PharmaEngine

A Study of NBTXR3 (PEP503) With Radiotherapy and Chemotherapy for Patients With Unresectable Rectal Cancer

clinicaltrials.gov | Phase I/II | Asia-Pacific | Recruiting

NBTXR3 – Head and Neck cancer – Phase I/II – Sponsored by PharmaEngine

A Study of NBTXR3 (PEP503) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

clinicaltrials.gov | Phase I/II | Asia-Pacific | Recruiting

00

HEAD AND NECK CANCER